Clinical Implication of High Sensitivity C-Reactive Protein for the Development of Dementia in Parkinson’s Disease
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and PurposeHigh-sensitivity C-reactive protein (hs-CRP) is the most widely studied biomarker of systemic inflammation. Its level has been reported to be associated with cognitive impairment. While dementia and cognitive impairment are common non-motor symptoms in advanced idiopathic Parkinson’s disease (PD), the clinical value of hs-CRP for predicting dementia in PD patients remains unclear. Therefore, the objective of this study was to clarify the relationship between hs-CRP levels and the development or progression of dementia in PD through evaluating hs-CRP levels in PD patients with or without dementia. MethodsA total of 112 PD patients without dementia (PD-D), 103 PD patients with dementia (PD+D), and 94 healthy controls were used in this study. The levels of hs-CRP and cognitive function were analyzed among these three groups. ResultsThe mean serum hs-CRP levels in PD-D and PD+D were 1.76±3.62 mg/dL and 1.44±2.78 mg/dL, respectively, which were significantly (p=0.02) higher than that (vs. 0.41±1.06 mg/dL) in healthy controls. However, the levels of hs-CRP were not significantly (p>0.05) different between PD-D and PD+D. ConclusionsOur results suggest that neuro-inflammation plays a role in the pathogenesis of PD. However, it does not significantly contribute to the development or the progression of dementia in PD patients.
Abstract
Background and PurposeHigh-sensitivity C-reactive protein (hs-CRP) is the most widely studied biomarker of systemic inflammation. Its level has been reported to be associated with cognitive impairment. While dementia and cognitive impairment are common non-motor symptoms in advanced idiopathic Parkinson’s disease (PD), the clinical value of hs-CRP for predicting dementia in PD patients remains unclear. Therefore, the objective of this study was to clarify the relationship between hs-CRP levels and the development or progression of dementia in PD through evaluating hs-CRP levels in PD patients with or without dementia. MethodsA total of 112 PD patients without dementia (PD-D), 103 PD patients with dementia (PD+D), and 94 healthy controls were used in this study. The levels of hs-CRP and cognitive function were analyzed among these three groups. ResultsThe mean serum hs-CRP levels in PD-D and PD+D were 1.76±3.62 mg/dL and 1.44±2.78 mg/dL, respectively, which were significantly (p=0.02) higher than that (vs. 0.41±1.06 mg/dL) in healthy controls. However, the levels of hs-CRP were not significantly (p>0.05) different between PD-D and PD+D. ConclusionsOur results suggest that neuro-inflammation plays a role in the pathogenesis of PD. However, it does not significantly contribute to the development or the progression of dementia in PD patients.
참고문헌 (23)
- Wilms H, "Inflammation in Parkinson’s diseases and other neurodegenerative diseases:cause and therapeutic implications", Curr Pharm Des, 13, pp.1925~1928 (2007)
- Orr CF, "A possible role for humoral immunity in the pathogenesis of Parkinson’s disease", Brain, 128(Pt 11), pp.2665~2674 (2005)
- Anang JB, "Predictors of dementia in Parkinson disease: a prospective cohort study", Neurology, 83, pp.1253~1260 (2014)
- Hirsch EC, "Neuroinflammation in Parkinson’s disease: a target for neuroprotection?", Lancet Neurol, 8, pp.382~397 (2009)
- Lindqvist D, "Cerebrospinal fluid inflammatory markers in Parkinson’s disease--associations with depression, fatigue, and cognitive impairment", Brain Behav Immun, 33, pp.183~189 (2013)
- McGeer PL, "Inflammation and neurodegeneration in Parkinson’s disease", Parkinsonism Relat Disord, 10(Suppl 1), pp.S3~S7 (2004)
- Mancinella A, "Is there a relationship between high C-reactive protein (CRP) levels and dementia?", Arch Gerontol Geriatr, 49(Suppl 1), pp.185~194 (2009)
- Engelhart MJ, "Inflammatory proteins in plasma and the risk of dementia: the rotterdam study", Arch Neurol, 61, pp.668~672 (2004)
- Hughes AJ, "Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases", J Neurol Neurosurg Psychiatry, 55, pp.181~184 (1992)
- American Psychiatric Association, "Diagnostic and statistical manualtext revision (DSM-IV-TRim, 2000)" (2000), American Psychiatric Association
- Hoehn MM, "Parkinsonism: onset, progression and mortality", Neurology, 17, pp.427~442 (1967)
- McKeith IG, "Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium", Neurology, 65, pp.1863~1872 (2005)
- Chen H, "Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease", Arch Neurol, 60, pp.1059~1064 (2003)
- Song IU, "Is there an association between the level of high-sensitivity C-reactive protein and idiopathic Parkinson’s disease? A comparison of Parkinson’s disease patients, disease controls and healthy individuals", Eur Neurol, 62, pp.99~104 (2009)
- Orr CF, "An inflammatory review of Parkinson’s disease", Prog Neurobiol, 68, pp.325~340 (2002)
- Yasojima K, "Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease", Brain Res, 887, pp.80~89 (2000)
- Di Napoli M, "C-reactive protein in intracerebral hemorrhage: time course, tissue localization, and prognosis", Neurology, 79, pp.690~699 (2012)
- Juma WM, "C-reactive protein expression in a rodent model of chronic cerebral hypoperfusion", Brain Res, 1414, pp.85~93 (2011)
- Schmidt R, "Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study", Ann Neurol, 52, pp.168~174 (2002)
- Song F, "Plasma biomarkers for mild cognitive impairment and Alzheimer’s disease", Brain Res Rev, 61, pp.69~80 (2009)
- Kravitz BA, "Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old", Alzheimers Dement, 5, pp.318~323 (2009)
- Hsuchou H, "C-reactive protein increases BBB permeability: implications for obesity and neuroinflammation", Cell Physiol Biochem, 30, pp.1109~1119 (2012)
- Lang AE, "Parkinson’s disease. First of two parts", N Engl J Med, 339, pp.1044~1053 (1998)